These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9366286)

  • 1. Treatment of congestive heart failure: experience with fosinopril.
    Blumenthal M
    Am J Hypertens; 1997 Oct; 10(10 Pt 2):289S-298S. PubMed ID: 9366286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of heart failure with fosinopril: an angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion.
    Mancia G; Giannattasio C; Grassi G
    Am J Hypertens; 1997 Oct; 10(10 Pt 2):236S-241S. PubMed ID: 9366279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.
    Greenbaum R; Zucchelli P; Caspi A; Nouriel H; Paz R; Sclarovsky S; O'Grady P; Yee KF; Liao WC; Mangold B
    Br J Clin Pharmacol; 2000 Jan; 49(1):23-31. PubMed ID: 10606834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure.
    Davis R; Coukell A; McTavish D
    Drugs; 1997 Jul; 54(1):103-16. PubMed ID: 9211084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosinopril. Clinical pharmacokinetics and clinical potential.
    Shionoiri H; Naruse M; Minamisawa K; Ueda S; Himeno H; Hiroto S; Takasaki I
    Clin Pharmacokinet; 1997 Jun; 32(6):460-80. PubMed ID: 9195116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure.
    Galatius S; Wroblewski H; Sørensen V; Haunsø S; Nørgaard T; Kastrup J
    J Card Fail; 1999 Mar; 5(1):17-24. PubMed ID: 10194656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension.
    Wagstaff AJ; Davis R; McTavish D
    Drugs; 1996 May; 51(5):777-91. PubMed ID: 8861547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.
    Langtry HD; Markham A
    Drugs Aging; 1997 Feb; 10(2):131-66. PubMed ID: 9061270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.
    Kostis JB; Garland WT; Delaney C; Norton J; Liao WC
    Clin Pharmacol Ther; 1995 Dec; 58(6):660-5. PubMed ID: 8529331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE inhibitors: review of four new agents.
    Binder SB
    Am Fam Physician; 1993 Oct; 48(5):851-7. PubMed ID: 8213415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril.
    Galatius-Jensen S; Wroblewski H; Emmeluth C; Bie P; Haunsø S; Kastrup J
    Cardiovasc Res; 1996 Dec; 32(6):1148-54. PubMed ID: 9015418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin-converting enzyme inhibitors: recent therapeutic aspect].
    Shionoiri H; Shigemasa T; Takasaki I
    Nihon Rinsho; 1997 Aug; 55(8):2067-74. PubMed ID: 9284425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
    MacFadyen RJ; Lee AF; Morton JJ; Pringle SD; Struthers AD
    Heart; 1999 Jul; 82(1):57-61. PubMed ID: 10377310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group.
    Erhardt L; MacLean A; Ilgenfritz J; Gelperin K; Blumenthal M
    Eur Heart J; 1995 Dec; 16(12):1892-9. PubMed ID: 8682023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity].
    Guazzi M; Lauri G; Melzi G; Cattadori G; Agostoni P
    Cardiologia; 1996 Jun; 41(6):527-33. PubMed ID: 8766415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive pharmacodynamics of fosinopril in patients with congestive heart failure.
    Ford NF; Natarajan C; Fulmor IE; Smith RA; Hui KK
    J Clin Pharmacol; 1995 Aug; 35(8):785-93. PubMed ID: 8522635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lisinopril: a review of its use in congestive heart failure.
    Simpson K; Jarvis B
    Drugs; 2000 May; 59(5):1149-67. PubMed ID: 10852646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.
    Sica DA; Cutler RE; Parmer RJ; Ford NF
    Clin Pharmacokinet; 1991 May; 20(5):420-7. PubMed ID: 1652404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Galvao M
    Heart Lung; 1990 Sep; 19(5 Pt 1):505-11. PubMed ID: 2211159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure.
    Szucs TD
    Am J Hypertens; 1997 Oct; 10(10 Pt 2):272S-279S. PubMed ID: 9366284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.